HMPL-689
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphomas
Conditions
Lymphomas
Trial Timeline
Aug 8, 2017 → Aug 2, 2023
NCT ID
NCT03128164About HMPL-689
HMPL-689 is a phase 1 stage product being developed by HUTCHMED for Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT03128164. Target conditions include Lymphomas.
What happened to similar drugs?
0 of 2 similar drugs in Lymphomas were approved
Approved (0) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04849351 | Phase 2 | Completed |
| NCT03786926 | Phase 1 | Terminated |
| NCT03128164 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphomas